MedPath

Verteporfin

Generic Name
Verteporfin
Brand Names
Visudyne
Drug Type
Small Molecule
Chemical Formula
C41H42N4O8
CAS Number
129497-78-5
Unique Ingredient Identifier
WU713D62N9

Overview

Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Background

Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Indication

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.

Associated Conditions

  • Subfoveal Choroidal Neovascularization (CNV)

FDA Approved Products

Visudyne
Manufacturer:QLT Ophthalmics, Inc.
Route:INTRAVENOUS
Strength:15 mg in 1 1
Approved: 2010/01/11
NDC:50236-001
Visudyne
Manufacturer:Bausch Health US LLC
Route:INTRAVENOUS
Strength:15 mg in 1 1
Approved: 2021/07/21
NDC:0187-5600
Visudyne
Manufacturer:Bausch & Lomb Incorporated
Route:INTRAVENOUS
Strength:15 mg in 1 1
Approved: 2023/02/24
NDC:24208-560

Singapore Approved Products

VISUDYNE FOR INJECTION 15 mg/vial
Manufacturer:Alcami Carolinas Corporation, Nippon Fine Chemical Co. Ltd (DP intermediate (Verteporfin Presome) manufacturer)
Form:INJECTION
Strength:15 mg/vial
Online:Yes
Approved: 2001/08/03
Approval:SIN11608P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath